Here are five things to know:
1. Within the orthopedics segment, J&J reported $2.34 billion in fourth quarter sales, a 2 percent drop compared to fourth quarter sales in 2016.
2. J&J’s orthopedic segment also saw a dip in 2017 full-year sales from $9.33 billion in 2016 to $9.25 billion in 2017. This represents a 0.8 percent decline.
3. U.S. orthopedic sales dropped 2.3 percent in the fourth quarter, totaling $1.38 billion. International sales also decreased from $965 million in 2016 to $950 million in the fourth quarter of 2017.
4. Concerning the company’s orthopedic medical devices, J&J’s hip and trauma lines were the only two segments to experience year-over-year growth. The hip line grew 2.4 percent to $1.39 billion while the
trauma line grew 1.8 percent to $2.61 billion.
5. In the fourth quarter, J&J reported major declines to its spine business line. For the year-end, the company reported a 4 percent drop in sales to $3.72 billion.
More articles on devices and implants:
Europe spinal implants market to hit $3.8B by 2024 — 4 observations
19 spine, orthopedic device companies to impact the industry in 2018
Medtronic, Safe Orthopaedics, Smith & Nephew & more: 8 device company notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
